Merck's Latest Inspiration Is Bolt-On Acquisition of Inspire Pharma for $430M
This article was originally published in The Pink Sheet Daily
Executive SummaryThe troubled specialty pharma offers Merck immediate revenues in ophthalmology, while the Big Pharma waits for approval of a new drug, Saflutan, for glaucoma and ocular hypertension.
You may also be interested in...
U.S. approval of the prostaglandin analogue adds to Merck’s ophthalmology portfolio, but it remains to be seen whether being preservative free confers tafluprost an advantage in a field that includes generics of the blockbuster Pfizer drug Xalatan.
Department of Justice has requested data on AzaSite, which Merck gained in its acquisition of Inspire Pharmaceuticals, Integrilin and Avelox.